Agile Therapeutics, Inc. provides revenue guidance for the year 2023. For the year, the company expects $25 million - $30 million in revenue largely due to Twirla.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3755 USD | +0.13% | -2.21% | -80.74% |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
1st Jan change | Capi. | |
---|---|---|
-80.74% | 2.57M | |
+4.45% | 109B | |
+10.93% | 105B | |
+0.96% | 22.25B | |
-11.72% | 22.09B | |
-7.77% | 18.68B | |
-38.36% | 17.58B | |
-10.24% | 16.85B | |
+4.79% | 13.76B | |
+38.40% | 12.46B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023